GO:0071559 response to transforming growth factor beta: Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0071559 response to transforming growth factor beta describes any cellular or organismal change triggered by a TGF-beta stimulus, including movement, secretion, enzyme production and gene expression.
• TGF-beta signals through type I and type II serine/threonine kinase receptors that phosphorylate SMAD2/3, which then partner with SMAD4 to regulate transcription.
• The pathway is context-dependent and can be tumor-suppressive in early cancer stages but pro-metastatic and immunosuppressive in advanced disease.
• SMAD7 provides a key negative feedback loop by binding activated type I receptors and preventing SMAD2/3 phosphorylation.
• Loss of TGF-beta receptor expression, as seen in retinoblastoma cells, can disrupt normal growth control and contribute to tumorigenesis.
• CRISPR knockout, point-mutation, knock-in and overexpression models are essential to dissect causal roles of TGF-beta pathway genes in disease.
Description
GO:0071559 response to transforming growth factor beta is a biological process ontology term that captures the full range of cellular and organismal responses to TGF-beta stimulation, including changes in movement, secretion, enzyme production and gene expression. TGF-beta is a pleiotropic cytokine that controls proliferation, differentiation, apoptosis, migration and immune function, and its signaling is frequently dysregulated in cancer, fibrosis and immune disorders. Because the pathway is highly context-dependent, researchers need precise experimental models to determine how individual genes contribute to TGF-beta responses in specific cell types. The term is therefore central to studies of development, tissue homeostasis, cancer biology and immunology.
response to transforming growth factor beta At A Glance
| GO ID | GO:0071559 |
|---|---|
| GO term | response to transforming growth factor beta |
| Ontology | biological_process |
| Synonym | response to TGF-beta stimulus; response to TGFbeta stimulus; response to transforming growth factor beta stimulus |
| Major function | Mediates cellular responses to TGF-beta, including SMAD phosphorylation, transcriptional regulation, growth arrest, differentiation, migration and immune modulation |
| Key receptors | TGFBR1 (ALK5), TGFBR2, TGFBR3 |
| Key SMADs | SMAD2, SMAD3, SMAD4, SMAD7 |
| Negative regulators | SMAD7, SKI, SNO N, STRAP |
| Disease relevance | Cancer, fibrosis, immune disorders, retinoblastoma |
What Is GO:0071559?
In practical terms, GO:0071559 describes any process that changes the state or activity of a cell or organism as a result of a transforming growth factor beta stimulus. This includes rapid cytoplasmic events such as SMAD phosphorylation and nuclear translocation, as well as slower transcriptional programs that alter proliferation, differentiation, migration and extracellular matrix production. The term also covers negative feedback mechanisms, such as SMAD7-mediated inhibition of receptor signaling, that shape the duration and intensity of the response.
Why Is response to transforming growth factor beta Important in Cell Biology?
GO:0071559 is important because TGF-beta signaling controls fundamental cell fate decisions and is one of the most frequently altered pathways in human disease. In cancer, TGF-beta can act as a tumor suppressor in early lesions but promote invasion, metastasis and immune evasion in advanced tumors. In immunology, TGF-beta is critical for regulatory T cell function and for limiting cytotoxic T lymphocyte responses, which has direct implications for anticancer immunotherapy. Understanding the precise molecular steps of this response is therefore essential for identifying therapeutic targets and biomarkers.
• TGF-beta signaling regulates cell proliferation, differentiation, apoptosis and migration in nearly all cell types.
• The pathway is a major tumor suppressor axis in early carcinogenesis, with loss of receptor or SMAD function contributing to cancer.
• In advanced cancer, TGF-beta promotes epithelial-mesenchymal transition, invasion and metastasis.
• TGF-beta suppresses cytotoxic T lymphocyte responses and supports regulatory T cell function, limiting antitumor immunity.
• SMAD7-mediated negative feedback is essential for preventing excessive or prolonged TGF-beta signaling.
• Dysregulated TGF-beta signaling is implicated in fibrosis, autoimmune disease and developmental disorders.
• The pathway is a target for anticancer therapies, including receptor kinase inhibitors and antisense oligonucleotides.
• Context-dependent outcomes require cell-type-specific CRISPR models to dissect gene function.
• TGF-beta receptor expression loss, as in retinoblastoma, can disrupt growth control and drive tumorigenesis.
• Understanding TGF-beta responses informs immunotherapy strategies, including checkpoint blockade combinations.
What Happens During response to transforming growth factor beta?
Ligand binding and receptor activation
In simple terms: TGF-beta binds to receptors on the cell surface and switches them on.
TGF-beta ligands bind to the type II receptor (TGFBR2), a constitutively active serine/threonine kinase, which then recruits and phosphorylates the type I receptor (TGFBR1/ALK5). This receptor complex formation is the first committed step in the response and determines downstream specificity. The type III receptor (TGFBR3/betaglycan) can present ligand to the type II receptor and modulate signaling.
SMAD phosphorylation and complex formation
In simple terms: Activated receptors tag SMAD proteins so they can carry the signal to the nucleus.
The activated type I receptor phosphorylates receptor-regulated SMADs, primarily SMAD2 and SMAD3, at their C-terminal SSXS motif. Phosphorylated SMAD2/3 then form heteromeric complexes with the common mediator SMAD4. This SMAD complex is the central transcriptional effector of TGF-beta responses.
Nuclear translocation and transcriptional regulation
In simple terms: The SMAD complex moves into the nucleus and turns genes on or off.
The SMAD2/3-SMAD4 complex translocates to the nucleus, where it binds DNA and interacts with transcription factors, coactivators and corepressors to regulate target gene expression. This leads to changes in genes controlling proliferation, differentiation, apoptosis, migration and extracellular matrix production. The transcriptional output is highly context-dependent and varies by cell type and cofactor availability.
Negative feedback by SMAD7
In simple terms: The cell makes a brake called SMAD7 to stop the signal from running too long.
SMAD7 is a TGF-beta-inducible inhibitory SMAD that binds activated type I receptors and prevents SMAD2/3 phosphorylation. SMAD7 can also recruit E3 ubiquitin ligases to target receptors for degradation. This negative feedback loop is essential for terminating the response and preventing excessive signaling.
Non-SMAD and crosstalk pathways
In simple terms: TGF-beta can also send signals through other routes besides SMADs.
In addition to SMAD signaling, TGF-beta can activate non-SMAD pathways such as MAPK, PI3K-AKT and Rho GTPases, which contribute to cytoskeletal changes, migration and survival. These pathways can crosstalk with SMAD signaling to fine-tune cellular outcomes. The integration of SMAD and non-SMAD signals determines the overall response to TGF-beta.
Key Genes Involved in GO:0071559 response to transforming growth factor beta
The following genes and proteins are central to the response to transforming growth factor beta and are frequently studied using CRISPR models.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TGFB1 | Encodes TGF-beta 1 ligand | Major isoform in immune regulation and fibrosis; knockout models show multi-organ inflammation |
| TGFBR1 | Type I receptor kinase (ALK5) | Phosphorylates SMAD2/3; point mutations alter kinase activity and substrate specificity |
| TGFBR2 | Type II receptor kinase | Binds ligand and activates TGFBR1; loss of expression is linked to retinoblastoma and cancer |
| TGFBR3 | Type III receptor (betaglycan) | Modulates ligand presentation and signaling; affects TGF-beta responsiveness |
| SMAD2 | Receptor-regulated SMAD | Transduces TGF-beta signals to nucleus; knockout affects differentiation and development |
| SMAD3 | Receptor-regulated SMAD | Mediates transcriptional responses; knockout mice show impaired immunity and wound healing |
| SMAD4 | Common mediator SMAD | Forms complexes with SMAD2/3; loss is common in pancreatic and colorectal cancer |
| SMAD7 | Inhibitory SMAD | Negative feedback regulator; induced by TGF-beta to prevent excessive signaling |
| SKI | Transcriptional corepressor | Binds SMAD complexes to repress TGF-beta target genes |
| SNO N | Transcriptional corepressor | Inhibits SMAD-mediated transcription; regulates differentiation |
| STRAP | SMAD-interacting protein | Modulates SMAD complex formation and signaling output |
| MAPK1 | Non-SMAD signaling kinase | Crosstalks with SMAD pathways to regulate migration and survival |
| PIK3CA | PI3K catalytic subunit | Mediates non-SMAD TGF-beta signals affecting survival and proliferation |
| RHOA | Rho GTPase | Regulates cytoskeletal changes and migration in response to TGF-beta |
| CDKN1A | p21 cell cycle inhibitor | TGF-beta-induced growth arrest mediator |
| CDKN2B | p15 cell cycle inhibitor | TGF-beta-induced growth inhibition in epithelial cells |
| JUNB | AP-1 transcription factor | TGF-beta target gene involved in proliferation and differentiation |
| SERPINE1 | PAI-1 inhibitor | Classic TGF-beta-induced gene used as a pathway activation marker |
How Is response to transforming growth factor beta Regulated?
The response to TGF-beta is tightly regulated at multiple levels. SMAD7 provides a rapid negative feedback loop by binding activated type I receptors and preventing SMAD2/3 phosphorylation. Receptor availability is controlled by endocytosis, ubiquitination and degradation, which determine the duration and intensity of signaling. Transcriptional cofactors and chromatin state further modulate SMAD complex activity, leading to cell-type-specific outcomes. Crosstalk with MAPK, PI3K-AKT and Wnt pathways can either enhance or inhibit TGF-beta responses depending on context.
response to transforming growth factor beta and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TGFBR2 | Retinoblastoma, cancer | Knockout in retinoblastoma cell lines; point mutation of kinase domain |
| SMAD4 | Pancreatic cancer, colorectal cancer | Knockout in organoids; knock-in of patient mutations |
| SMAD7 | Inflammatory bowel disease, fibrosis | Overexpression and knockout in intestinal epithelial cells |
| TGFB1 | Fibrosis, immune dysregulation | Knockout mice; overexpression in fibroblasts |
| CDKN1A | Cell cycle dysregulation in cancer | Point mutation of TGF-beta-responsive promoter; knockout |
Cancer: dual tumor suppressor and oncogenic roles
TGF-beta signaling is a major tumor suppressor pathway in early carcinogenesis, where it induces growth arrest and apoptosis. However, in advanced tumors, TGF-beta promotes epithelial-mesenchymal transition, invasion, metastasis and immune evasion. Loss of TGF-beta receptor expression, as observed in retinoblastoma cells, can disrupt normal growth control and contribute to tumorigenesis. These dual roles make the pathway a challenging but important therapeutic target.
Immune regulation and immunotherapy
TGF-beta is a potent immunosuppressive cytokine that inhibits cytotoxic T lymphocyte activation and supports regulatory T cell function. This limits antitumor immunity and contributes to resistance to immune checkpoint blockade. Understanding how TGF-beta and SMAD signaling shape T cell responses is critical for designing combination immunotherapies.
Fibrosis and tissue remodeling
Excessive TGF-beta signaling drives fibroblast activation and extracellular matrix deposition, leading to fibrosis in lung, liver and kidney. SMAD3 and SMAD4 are central mediators of these fibrotic responses. Targeting TGF-beta signaling is therefore an active area in antifibrotic drug development.
Developmental and genetic disorders
Mutations in TGF-beta pathway components can cause developmental defects and connective tissue disorders. For example, loss of TGFBR2 expression is linked to retinoblastoma and other cancers. Studying these mutations in model systems helps clarify genotype-phenotype relationships.
From response to transforming growth factor beta-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TGFBR2 abolish TGF-beta-induced growth arrest? | TGFBR2 knockout cell line |
| Does a specific SMAD3 point mutation alter transcriptional output? | SMAD3 point-mutation knock-in |
| Can SMAD7 overexpression block TGF-beta signaling? | SMAD7 overexpression stable line |
| Does TGF-beta induce SMAD2/3 nuclear translocation? | Endogenously tagged SMAD2/3 knock-in |
| Which genes are required for TGF-beta-mediated immune suppression? | CRISPR library screening in T cells |
| Does a patient-derived SMAD4 mutation impair complex formation? | SMAD4 knock-in of patient variant |
How to Study the response to transforming growth factor beta Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify TGF-beta target genes and pathway signatures |
| Phospho-SMAD Western blot | SMAD2/3 phosphorylation status | Confirm pathway activation or inhibition |
| Immunofluorescence | SMAD nuclear translocation | Visualize single-cell responses |
| CRISPR knockout screening | Gene requirement for TGF-beta response | Discover novel regulators |
| Proteomics | Protein complex composition | Map SMAD interactome |
| Luciferase reporter assay | SMAD transcriptional activity | Quantify pathway output |
| Flow cytometry | Immune cell phenotype and function | Assess TGF-beta effects on T cells |
| ChIP-seq | SMAD DNA binding sites | Identify direct transcriptional targets |
Transcriptomic profiling
RNA-seq after TGF-beta stimulation identifies global changes in gene expression and can reveal cell-type-specific transcriptional programs. Comparing wild-type and CRISPR knockout cells pinpoints genes that are causally required for specific responses.
Phospho-SMAD immunoblotting and imaging
Western blotting for phosphorylated SMAD2/3 is a standard readout of pathway activation. Immunofluorescence can visualize SMAD nuclear translocation and subcellular localization in single cells.
CRISPR screening
Genome-wide CRISPR knockout or activation screens can identify positive and negative regulators of TGF-beta responses. These screens are particularly useful for uncovering context-specific modifiers of SMAD signaling.
Proteomics and interactomics
Affinity purification coupled with mass spectrometry can map SMAD complex composition and identify cofactors that modulate transcriptional output. Proximity labeling approaches can capture dynamic interactions after TGF-beta stimulation.
How CRISPR Can Be Used to Study GO:0071559 response to transforming growth factor beta
Knockout
CRISPR knockout of TGF-beta pathway genes such as TGFBR2, SMAD2, SMAD3 or SMAD4 can abolish specific responses and reveal essential components. Knockout models are particularly useful for distinguishing redundant from non-redundant functions.
Point Mutation
Point mutations in kinase domains or SMAD phosphorylation sites can dissect catalytic activity from scaffolding functions. For example, mutating the SSXS motif in SMAD2 prevents receptor-mediated phosphorylation and nuclear translocation.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows real-time tracking of endogenous SMAD proteins and receptor dynamics. Patient-derived mutations can be introduced by knock-in to study disease mechanisms.
Overexpression
Overexpression of SMAD7 or other negative regulators can suppress TGF-beta signaling and test whether pathway inhibition is sufficient to alter a phenotype. Overexpression of constitutively active receptors can also mimic ligand stimulation.
How EDITGENE Supports response to transforming growth factor beta Research
Researchers studying response to transforming growth factor beta-related genes often need to determine whether a candidate gene is causally involved in a specific cellular response. EDITGENE provides validated CRISPR models and screening services to accelerate this discovery process.
Contact EDITGENE today to design your custom CRISPR model for response to transforming growth factor beta research.
Frequently Asked Questions About response to transforming growth factor beta
What is GO:0071559 response to transforming growth factor beta?
GO:0071559 is a biological process ontology term describing any cellular or organismal change caused by a TGF-beta stimulus, including changes in gene expression, movement, secretion and enzyme production.
What genes are involved in response to transforming growth factor beta?
Key genes include TGFB1, TGFBR1, TGFBR2, TGFBR3, SMAD2, SMAD3, SMAD4 and SMAD7, which mediate ligand binding, receptor activation and transcriptional regulation.
How does TGF-beta signal inside the cell?
TGF-beta binds type II receptors, which activate type I receptors to phosphorylate SMAD2/3; these form complexes with SMAD4 and move to the nucleus to regulate transcription.
What is the role of SMAD7 in TGF-beta signaling?
SMAD7 is an inhibitory SMAD induced by TGF-beta that binds activated type I receptors and prevents SMAD2/3 phosphorylation, providing negative feedback.
Why is TGF-beta important in cancer?
TGF-beta can suppress early tumor growth but later promote invasion, metastasis and immune evasion, making it a dual-role pathway in cancer.
How does TGF-beta affect the immune system?
TGF-beta suppresses cytotoxic T lymphocyte responses and supports regulatory T cells, limiting antitumor immunity.
What diseases are linked to TGF-beta signaling?
Diseases include cancer, fibrosis, autoimmune disorders and developmental defects, with receptor loss linked to retinoblastoma.
How can CRISPR be used to study TGF-beta responses?
CRISPR knockout, point mutation, knock-in and overexpression models allow causal testing of pathway genes in specific cell types.
What methods are used to measure TGF-beta pathway activity?
Common methods include phospho-SMAD Western blotting, RNA-seq, luciferase reporter assays and immunofluorescence for SMAD nuclear translocation.
What is the difference between SMAD2 and SMAD3?
Both are receptor-regulated SMADs, but they have distinct target gene sets and knockout phenotypes, reflecting non-redundant functions.
Conclusion
GO:0071559 response to transforming growth factor beta is a central biological process that governs cell proliferation, differentiation, migration and immune function through SMAD-dependent and independent mechanisms. Its dysregulation contributes to cancer, fibrosis and immune disorders, making it a high-priority area for therapeutic development. CRISPR-based models are indispensable for dissecting the causal roles of individual pathway components and for identifying new drug targets.
References
- 1. Derynck R et al.. 2019. Specificity, versatility, and control of TGF-β family signaling.. Sci Signal 12(570) PMID: 30808818
- 2. Chandiran K et al.. 2023. The diverse effects of transforming growth factor-β and SMAD signaling pathways during the CTL response.. Front Immunol 14:1199671 PMID: 37426662
- 3. Wrzesinski SH et al.. 2007. Transforming growth factor-beta and the immune response: implications for anticancer therapy.. Clin Cancer Res 13(18 Pt 1):5262-70 PMID: 17875754
- 4. Wahl SM. 2007. Transforming growth factor-beta: innately bipolar.. Curr Opin Immunol 19(1):55-62 PMID: 17137775
- 5. Ikushima H et al.. 2011. Biology of transforming growth factor-β signaling.. Curr Pharm Biotechnol 12(12):2099-107 PMID: 21619537
- 6. Budi EH et al.. 2017. Transforming Growth Factor-β Receptors and Smads: Regulatory Complexity and Functional Versatility.. Trends Cell Biol 27(9):658-672 PMID: 28552280
- 7. Denissova NG et al.. 2000. Transforming growth factor beta -inducible independent binding of SMAD to the Smad7 promoter.. Proc Natl Acad Sci U S A 97(12):6397-402 PMID: 10823886
- 8. Horie K et al.. 1998. Lack of transforming growth factor-beta type II receptor expression in human retinoblastoma cells.. J Cell Physiol 175(3):305-13 PMID: 9572475
